Inhibition of Liver Metastasis of Human Gastric Carcinoma by Angiogenesis Inhibitor TNP‐470

Open Access
Publisher Website
Google Scholar
Abstract
The anti‐tumor and anti‐metastatic effects of TNP‐470, an angiogenesis inhibitor, and mitomycin C (MMC), a representative anti‐neoplastic agent, were investigated using our established liver‐metastasizing gastric carcinoma line, AZ‐H5c. AZ‐H5c was injected into the spleen of nude mice which had been randomly divided into 4 groups; a control group given saline solution, a group receiving 15 mg/kg TNP‐470, a group receiving 30 mg/kg TNP‐470 and a group receiving 2 mg/kg MMC. TNP‐470 was given s.c. on alternate days for 5 weeks from day 10 after intrasplenic injection, and MMC was administered intraperitoneally (i.p.) once a week from day 10 after intrasplenic injection. In the control group, liver metastasis developed in 13 of 16 mice (81%). Liver metastasis developed in 6 of 11 mice (55%) receiving MMC. In contrast, liver metastasis developed in 4 of 8 mice (50%) receiving 15 mg/Kg TNP‐470, and in 0 of 14 mice (0%) receiving 30 mg/kg TNP‐470. However, TNP‐470 had no effect on the tumor growth. These results indicate that the angiogenesis inhibitor TNP‐470 has a strong inhibitory activity against in vivo liver metastasis of human gastric carcinoma.